Intelerad Medical Systems announced the availability of a Frost & Sullivan analysis detailing the strengths of their medical imaging workflow solutions. The analysis was written in conjunction with Frost & Sullivan’s investigation of the medical imaging workflow solutions market, which led to Intelerad winning the 2013 Frost & Sullivan Best Practices Award for North America Entrepreneurial Company of the Year.

One thousand days, 1,000 C-arms: this is the result three years after the introduction of the Ziehm Solo. As one of the most compact and flexible C-arms, the Ziehm Solo adjusts to the special demands and requirements of clinics. More and more users from orthopedics and trauma opt for Ziehm Imaging’s multi-talent for intraoperative imaging. The 1,000th Ziehm Solo will be delivered to the Clinica Santa Elena in Malaga, Spain.

The U.S. Navy has awarded Agfa Healthcare a contract to upgrade more than 30 ships in the U.S. Navy fleet to the latest digital radiography (DR) solutions with Agfa Healthcare's DX-D 400, DX-D 100 and other systems. To be used along with Agfa Healthcare's Impax picture archive and communications system (PACS) and TalkStation voice recognition system for diagnostic reporting, this end-to end solution will provide the Navy with improved, efficient workflow from image acquisition to study reporting.

TeamBest companies are planning for a major expansion by diversifying its area of expertise and product lines, to meet the growing demands of an increasing and aging population. Earlier this year, Best Medical International (BMI) purchased Envisioneering Medical Technologies’ assets including TargetScan Touch, an ultrasound based stereotactic biopsy guidance and tumor localization system. TargetScan data can be used to generate a predictive model of tumor locations and provide for micro-invasive curative techniques using EBRT (external beam radiation therapy) or brachytherapy or combination. Because of its ability to target and record biopsy locations the TargetScan Touch can provide for prostate cancer management protocols such as active surveillance and focal therapy.

Angiotech Pharmaceuticals Inc. announced that it entered into a definitive agreement to sell certain of its subsidiaries, comprising Angiotech's interventional products business, to Argon Medical Devices Inc., a portfolio company of RoundTable Healthcare Partners, for $362.5 million in cash consideration. Angiotech expects the transaction will close prior to the end of April 2013.

Navidea Biopharmaceuticals Inc. announced that collaborators at Molecular Neuroimaging LLC (MNI) in New Haven, Conn., have enrolled the first subject in a clinical study to investigate the performance of [123I] NAV5001 in a single photon emission computed tomography (SPECT) imaging imaging procedure in connection with Navidea’s program to evaluate NAV5001 in Dementia with Lewy Bodies (DLB).